BioCentury
ARTICLE | Emerging Company Profile

Metal smithing

How Forge's metal-binding chemistry can tackle tough metalloenzyme targets

August 22, 2016 7:00 AM UTC

Forge Therapeutics Inc. is using a library of metal-binding pharmacophores that avoid known pharmacologic and safety liabilities of a common metal-binding motif to create inhibitors of metalloenzymes, starting with notoriously tough targets.

Forge's lead program is a broad-spectrum Gram-negative antibiotic targeting UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase (LpxC)...